There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Epizyme (NASDAQ: EPZM), TG Therapeutics (NASDAQ: TGTX) and Celldex (NASDAQ: CLDX) with bullish sentiments.
Epizyme (NASDAQ: EPZM)
“Tazemetostat is currently being studied in clinical programs in INI-1 negative tumors, synovial sarcomas, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and mesothelioma. The data presented at ASCO support tazemetostat’s potential in mesothelioma and our expectations for tazemetostat launch.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 20.0% and a 62.3% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $24.13, representing a 40.3% upside.
In a report issued on May 21, H.C. Wainwright also assigned a Buy rating to the stock with a $25 price target.
TG Therapeutics (NASDAQ: TGTX)
According to TipRanks.com, White is a 5-star analyst with an average return of 26.7% and a 55.2% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Synthetic Biologics Inc, and Karyopharm Therapeutics.
TG Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $32.50.
Celldex (NASDAQ: CLDX)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Celldex (NASDAQ: CLDX) today and set a price target of $2.15. The company’s shares closed on Friday at $0.59, close to its 52-week low of $0.58.
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.0% and a 36.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Celldex has an analyst consensus of Moderate Buy, with a price target consensus of $2.58.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.